Author

M Broekema

Observed names: M. Broekema, Matthais Broekema

Institution: Bristol-Myers Squibb (United States)

Observed institutions: University Medical Center Groningen, University of Groningen, Bristol-Myers Squibb (United States)

OpenAlex ID: A5111905707

Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody

2013 · M Reilly, R M Miller, et al. · Clinical Pharmacology & Therapeutics · 122

Airway eosinophilia in remission and progression of asthma: Accumulation with a fast decline of FEV1

2010 · M. Broekema, F. Volbeda, et al. · Respiratory Medicine · 77

Can AMP induce sputum eosinophils, even in subjects with complete asthma remission?

2010 · Franke Volbeda, Nick HT ten Hacken, et al. · Respiratory Research · 12

Discovery of Novel TLR7 Agonists as Systemic Agent for Combination With aPD1 for Use in Immuno-oncology

2024 · Yam B. Poudel, Liqi He, et al. · ACS Medicinal Chemistry Letters · 5

Pathological Changes in the Airways of Smoking Asthma Patients.

2009 · M Broekema, W Timens, et al. · 1

Works count: 6

Citation count: 217

H-index: 4

I10-index: 3